Abattis Bioceuticals Corp. (ATTBF)

[Recentiy03]

Abattis's Valuation Post-Allard

Presumably whenever the Judge gets around to ruling against the the government (and indirectly Licensed Producers) in the Allard et al case, Abattis's valuation will remain more or less unchanged, as they're not currently licensed, and hope appears lost on that front, right?

After all, we've heard no news of a larger safe, and without one navigating Health Canada's ever-changing path of regulatory roadblocks appears impossible in its politicized game of winners and losers. Speaking of lawsuits, there are rumors of a class action against Health Canada for mishandling the whole process, but as it seems likely patients will be able to grow their own medicine post-Allard, that issue may be moot.

The company's cap has lately been nesting around $6.3M, but it's hard to say what exactly that's based on. Clearly, the company has been wondering the same thing http://www.abattis.com/s/news.asp?ReportID=705379

Anticipated status as a licensed producer undeniably fueled last year's surge in PPS, although things have sufficiently tempered due to the various regulatory "hiccups" that I can't imagine anticipating becoming an LP provides much, if indeed any, of the current valuation.

So what's left?

On the surface, Phytalab appears to be the company's most tangible asset, regardless of how much revenue they're generating. Perhaps more important than its revenue potential is its data collection, which in turn can be used by iJuana, Northern Vine, and Biocell. Moreover, they have an existing network of clients in Washington who may be interested in using Biocubes...

Yes, Biocubes are still sitting in a warehouse somewhere in British Columbia, still being tested. And yet, tests to date have seemingly produced quite fruitful yields, and I believe this product has significant potential down the road. Keep and eye on http://biocubesystems.com and note the following: "Biocube plans to relocate the proprietary grow chamber to a i-502 location in Washington state in the near future and is preparing to sell grow systems that are ready for market. Biocube's goal in relation to this product remains to develop a superior sustainable growth chamber for use in the medical marijuana industry as well as produce markets."

Brazos Minshew was recently appointed Chief Science Officer, and recall the recent 5-year deal with Empirical Labs in Colorado. We know they're working on a bunch of new products with a wide aray of markets; hopefully whatever products are developed can generate some sort of ROI http://www.biocelllabs.com

Keep an eye on http://www.northernvine.ca to go live, as well.

All-in-all, I think there is reason to believe significant progress has been made and that the company has successfully managed to get away from reliance on becoming an LP.

They just appointed a new IR person, and Bill Flemming has only been CEO for less than 4 months...one can only imagine they plan to announce significant progress in one area or another BEFORE the Allard judge rules...after all, management continue to award themselves incentive options...